Role of p 53 codon 72 polymorphism in EBV-related gastric cancer
Role of p 53 codon 72 polymorphism in EBV-related gastric cancer
批准号:
17590297
负责人:
MURAI Yoshihiro
金额:
$1.41万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
2005
资助国家:
日本
项目状态:
已结题
起止时间:
2005 至 2006
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Twenty-three EBV-positive cases (5.3%) were detected in 431 gastric cancer cases by EBV encoded small RNA1 (EBER1) in situ hybridization. p53 codon72 polymorphisms were evaluated in 23 EBV-positive gastric cancers by DNA direct sequencing; arginine (arg) was found in 7 (30.4%), proline (pro) in 0 (0%), and arg/pro in 16 (69.6%) cases. In 160 EBV-negative cases, arg was found in 88 (55.0%), pro in 10 (6.3%), and arg/pro in 62 (38.7%) tumors. The frequency of the arg/pro type was significantly higher in EBV-positive than negative cases (p<0.05). DNA mutations were analyzed in exon 4-8 of the p53 gene in 23 EBV-positive and age/sex-matched EBV-negative cases. There were seven homozygous mutations in five EBV-positive cases and five homozygous mutations in five EBV-negative cases. A nonsense mutation was included in one EBV-positive case and one negative case. On the other hand, there were six heterozygous mutations in four EBV-positive cases and two heterozygous mutations in two EBV-negative cases. Double mutations were found more in EBV-positive cases than negative cases. Five of six patients with heterozygous mutations were of the arg/pro type. The other tumor was of the arg type with double heterozygous mutations. It has been reported that an arg-containing allele is preferentially mutated in heterozygotes and mutant p53 binds and inhibits the apoptotic function of the p53 family proteins. Therefore, arg mutant protein in the patients with the arg/pro type may inhibit the apoptotic function. Such condition may be preferable for virus to survive.
期刊论文(3)
专著(0)
科研奖励(0)
会议论文
DOI:
10.1111/j.1349-7006.2006.00354.x
发表时间:
2007-01-01
期刊:
CANCER SCIENCE
影响因子:
5.7
作者:
[Murai, Yoshihiro, Zheng, Hua-Chuan, Takano, Yasuo]
通讯作者:
Takano, Yasuo
国内基金
海外基金
登录
查看更多内容
EB病毒核抗原1通过靶向PPP1CA稳定自身表达及其调控EBV潜伏感染的作用和机制研究
-
批准号:2026JJ50144
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:卢建红
-
依托单位:
EBV-RBM4通过稳定HOXB13 mRNA促进鼻咽癌细胞上皮-间质转化及恶性进展
-
批准号:2026JJ81710
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:陈志
-
依托单位:
EBV上调E3连接酶RNF114抑制鼻咽癌细胞Necroptosis机制研究
-
批准号:2026JJ81963
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:刘文斌
-
依托单位:
EBV-miR-BART19-3p抑制GADD45B增强cyclinB1/CDK1结合促进EBV相关胃癌细胞增殖的机制研究
-
批准号:2025JJ81046
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:阳静
-
依托单位:
聚合物分子刷激动剂调控三级淋巴组织丰度预防 EBV感染
-
批准号:
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
基于VSV的新型多价EBV疫苗研发及保护
机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2025
-
负责人:孔祥炜
-
依托单位:
EBV高危亚型编码的BALF2-HR蛋白上调HLA-II类分子促进鼻咽癌免疫逃逸的机制研究
-
批准号:2025JJ60152
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:葛军尚
-
依托单位:
EBV诱导鼻咽癌免疫治疗抵抗的作用及其
机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2025
-
负责人:杨琦
-
依托单位:
PI3K 抑制剂抑制EBV阳性淋巴瘤的分子机制研究
-
批准号:JCZRLH202500224
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
Vdelta2-T细胞外泌体疫苗携带IFN-gamma和TNF-alpha诱导抗原提呈细胞成熟并促进EBV肿瘤免疫应答的机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:15.0万元
-
批准年份:2024
-
负责人:王系伟
-
依托单位: